MedPath

Early detection of Hereditary Breast Cancer by Monitoring MicroRNA expression in Nipple Aspirate Fluid

Recruiting
Conditions
Breast cancer, hereditary breast cancer
Registration Number
NL-OMON24687
Lead Sponsor
Vrienden UMC Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
620
Inclusion Criteria

> 20% lifetime risk of developing breast cancer (e.g. due to germline mutations such as BRCA1 or BRCA2)
- Previous DCIS/invasive breast cancer
- Female = 18 years of all ethnic backgrounds

Exclusion Criteria

- Bilateral ablative breast surgery
- Bilateral breast reduction with nipple graft
- Pregnancy or lactation
- Active breast infection
- Disseminated breast cancer

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Predictive value of biomarkers in early breast cancer development, with a primary focus on miRNA.<br>- To establish biomarker profiles in NAF, follow them in time and establish a correlation with breast cancer development.<br>- To determine threshold values of these biomarkers that point to a significant risk of imminent breast cancer development thereby indicating the right time of prophylactic breast surgery.
Secondary Outcome Measures
NameTimeMethod
Secondary Objectives:<br>- To assess discomfort, uncertainty and distress experienced by subjects.<br>- To set up a Biobank of blood samples and serum of women at increased breast cancer risk, providing opportunities to correlate molecular biomarker results in NAF to those in serum and/or plasma in the near future.
© Copyright 2025. All Rights Reserved by MedPath